Analysts Set Expectations for CGTX FY2026 Earnings

Cognition Therapeutics, Inc. (NASDAQ:CGTX) – Analysts at Brookline Capital Markets lifted their FY2026 EPS estimates for shares of Cognition Therapeutics in a report released on Friday, May 8th. Brookline Capital Markets analyst F. Ahmed now expects that the company will post earnings per share of ($0.44) for the year, up from their prior estimate of ($0.46). The consensus estimate for Cognition Therapeutics’ current full-year earnings is ($0.31) per share.

CGTX has been the topic of a number of other reports. raised shares of Cognition Therapeutics to a “strong-buy” rating in a research report on Tuesday, February 3rd. Chardan Capital reaffirmed a “buy” rating and issued a $4.00 target price on shares of Cognition Therapeutics in a research report on Friday, March 27th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Cognition Therapeutics in a research report on Friday, March 27th. Three research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Cognition Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $3.33.

Cognition Therapeutics Trading Down 2.5%

Shares of CGTX opened at $1.18 on Tuesday. The firm’s fifty day simple moving average is $1.06 and its 200-day simple moving average is $1.31. The firm has a market capitalization of $105.43 million, a price-to-earnings ratio of -4.92 and a beta of 1.81. Cognition Therapeutics has a twelve month low of $0.22 and a twelve month high of $3.83.

Cognition Therapeutics (NASDAQ:CGTX) last announced its quarterly earnings data on Thursday, May 7th. The company reported ($0.05) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.06) by $0.01.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the stock. DAVENPORT & Co LLC grew its position in Cognition Therapeutics by 6.8% during the 4th quarter. DAVENPORT & Co LLC now owns 2,871,836 shares of the company’s stock worth $3,877,000 after purchasing an additional 182,500 shares during the last quarter. Vanguard Group Inc. grew its position in Cognition Therapeutics by 105.6% during the 3rd quarter. Vanguard Group Inc. now owns 2,681,613 shares of the company’s stock worth $3,620,000 after purchasing an additional 1,377,263 shares during the last quarter. Northwestern Mutual Wealth Management Co. grew its position in Cognition Therapeutics by 11,695.3% during the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 2,060,282 shares of the company’s stock worth $2,781,000 after purchasing an additional 2,042,815 shares during the last quarter. Acadian Asset Management LLC grew its position in Cognition Therapeutics by 814.1% during the 1st quarter. Acadian Asset Management LLC now owns 1,007,586 shares of the company’s stock worth $422,000 after purchasing an additional 897,353 shares during the last quarter. Finally, Chescapmanager LLC grew its position in Cognition Therapeutics by 98.1% during the 3rd quarter. Chescapmanager LLC now owns 997,029 shares of the company’s stock worth $1,346,000 after purchasing an additional 493,770 shares during the last quarter. 43.35% of the stock is owned by hedge funds and other institutional investors.

About Cognition Therapeutics

Cognition Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing disease-modifying therapies for neurodegenerative disorders, with an emphasis on Alzheimer’s disease. The company’s lead investigational candidate, CT1812, is an oral small molecule that antagonizes the sigma-2 receptor complex to protect synapses from amyloid-beta oligomer toxicity. By targeting a novel mechanism of action, Cognition Therapeutics aims to slow or reverse cognitive decline in patients living with Alzheimer’s disease.

CT1812 has successfully completed Phase 1 safety studies and preliminary Phase 2a trials, and is currently being evaluated in multiple Phase 2 clinical studies across North America and Europe in patients with mild-to-moderate Alzheimer’s disease.